The extreme dilution (up to ~5.6x current shares outstanding) will likely overwhelm any premium pricing benefit. Monitor shareholder vote outcome and the investor's final funding election (RAIN tokens vs USD). The 36-month put right creates ongoing overhang. Watch for potential Nasdaq listing standard issues given the massive share issuance.
Price Chart
Executive Summary
Enlivex announced a $400M private placement of ordinary shares at a premium to market price, with proceeds intended to fund its RAIN token treasury strategy and Allocetra clinical development. The massive size relative to its $72M market cap implies extreme dilution, though the premium pricing and institutional backing provide some offset. The transaction requires shareholder approval and includes a 36-month put right for an additional $400M in shares.
Key Facts
- $400,000,000 private placement of ordinary shares at $5.00-$6.00 per share
- Pricing represents 17.4%-40.8% premium to July 27, 2026 closing price
- Investor elected to fund with RAIN tokens, election changeable before closing
- Company has 36-month put right to require investor to purchase up to an additional $400,000,000 in shares
- Transaction requires shareholder approval under Nasdaq Rules 5635(a)/(b) and Israeli Companies Law
- Proceeds to fund RAIN token treasury strategy and Allocetra clinical development
- Company had 237,381,498 ordinary shares outstanding as of December 31, 2025
Financial Impact
$400M gross proceeds from private placement, representing approximately 5.6x current market cap of $72M
Risk Factors
- Massive dilution from up to 80M+ new shares relative to 237M outstanding
- Shareholder approval may fail given extreme dilution
- RAIN token price volatility could impair treasury value
- Nasdaq may question continued listing with such a large share count increase
- 36-month put right creates persistent dilution overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-081993 |
| Document: ea0299418-6k_enlivex.htm | 0001213900-26-081993 |
| Document: 0001213900-26-081993-index-headers.html | 0001213900-26-081993 |
| Document: 0001213900-26-081993-index.html | 0001213900-26-081993 |
| Document: 0001213900-26-081993.txt | 0001213900-26-081993 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $2.70 (−1457.09%) |
Oct 22, 2026 5d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.70 (+1457.09%) |
Oct 22, 2026 5d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.70 (+1457.09%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.70 (−1204.35%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.70 (−1204.35%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.70 (+425.29%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.70 (+317.70%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.70 (+70.89%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.70 (+38.46%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.70 (+20.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers